Lilly's Bimagrumab in Combination with Wegovy Demonstrates Significant Fat Loss While Preserving Muscle Mass

Gelonghui June 23 | Research shows that patients using Novo Nordisk's weight-loss drug Wegovy in combination with Eli Lilly's experimental drug bimagrumab can effectively maintain muscle mass while losing weight. According to results presented at the American Diabetes Association annual meeting held in Chicago on Monday, patients on the combination therapy experienced a 22.1% reduction in body weight over 48 weeks, with 92.8% of the loss attributed to fat. Notably, 100% of the weight loss in the bimagrumab monotherapy group came from fat, with lean body mass increasing by 2.5%.